
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated July 12, 2023, titled "APL Healthcare receives USFDA Approval for Sevelamer Hydrochloride Tablets 400 mg and 800 mg.".
Filed with NSE ·

Aurobindo Pharma Limited has informed the Exchange regarding a press release dated July 12, 2023, titled "APL Healthcare receives USFDA Approval for Sevelamer Hydrochloride Tablets 400 mg and 800 mg.".
6ix hasn’t read this filing yet.
Follow Aurobindo Pharma into a list and get an email when it puts out news.
Follow Aurobindo Pharma